Insider buying last 90 days
No open-market insider purchases were filed for BLFS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BLFS insider filing, plotted on the chart in Gekko.Open BLFS in Gekko
No recent trading data for BLFS. The last close Gekko holds is Oct 5, 2026, so the figures on this page may be out of date.
NASDAQ: BLFS
BioLife Solutions (BLFS) Stock Analysis & Forecast
Oct 5 close
$38.61+1.31 (+3.5%)
Gekko Brief
Oct 5 closeBioLife Solutions closed at $38.61 on 5 October 2026, +3.5% on the day. The price sits above both the 50-day ($35.70) and 200-day ($26.62) moving averages, inside a 52-week range of $17.86 to $39.76. The GekkoIndex reads 52.2, in the Neutral zone, up 5.8 points over five sessions. Gekko Fair Value is $33.82, so the price is 14.2% above it.
The next earnings report is due on 5 November 2026, 24 days away (after close). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 7.2% across the report. Seasonally, the next 20 trading days from this point averaged +5.6% over the last 5 years, rising in 2 of them.
8 firms rate the stock: 0 buy, 8 hold and 0 sell, with a consensus target of $31.00. A typical daily move is about 2.9%, and a typical 20-day move about 9.9%. On the swing-trade checklist, 1 item reads supportive and 2 read as a headwind (fair value, earnings risk).
A plain summary of the figures as of the Oct 5, 2026 close.
BioLife Solutions price vs fair value
Close $38.61200-day averageGekko Fair Value $33.82
BioLife Solutions quick facts
- Market cap
- $1.89B
- P/E ratio
- 39
- Forward P/E
- 238.1
- EPS, TTM
- $0.99
- Revenue, TTM
- $106.7M
- Profit margin
- 54.3%
- Dividend yield
- —
- Beta
- 1.82
- Volume
- 4.45M avg 1.20M
- 1-year return
- +49.0%
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±9.9%
- 50-day average
- $35.70
- 200-day average
- $26.62
- Next earnings
- Nov 5 after close
- Shares outstanding
- 48.92M
BioLife Solutions swing-trade checklist
BioLife Solutions scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $38.61 is above the 50-day ($35.70) and 200-day ($26.62) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52.2, Neutral
Reading 52.2 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
14.2% above
Price is 14.2% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+5.6% on average
From this point in the calendar, the next 20 trading days averaged +5.6% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BioLife Solutions stock chart and price history
BioLife Solutions closed at $38.61 on Oct 5, 2026, +49.0% over the past year, inside a 52-week range of $17.86 to $39.76.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.7%
- 3 months
- +38.2%
- 6 months
- +100.4%
- 1 year
- +49.0%
The full BLFS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLFS in Gekko
Follow BioLife Solutions through every session
Put BLFS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BLFS in GekkoFree for 7 days. No credit card required.
About BioLife Solutions
BioLife Solutions supplies tools and services used in the production of cell and gene therapies, selling to customers in the United States, Canada, Europe, the Middle East, Africa and other regions. Its work supports biologic therapy development at every stage, from early research through full-scale manufacturing. The company is recognized for biopreservation media such as HypoThermosol FRS and CryoStor, formulated to limit cell damage during preservation, along with its ThawSTAR line of automated thawing devices that control heat and timing when warming vials and cryobags.
Beyond these core products, BioLife Solutions offers cloud-connected evo shipping containers for moving and storing temperature-sensitive biologics and pharmaceuticals without active refrigeration, as well as liquid nitrogen freezers, cryogenic equipment, accessories and storage services for biological and pharmaceutical materials. Goods reach customers both through direct sales and through a network of outside distributors.
The company was founded in 1987 and is headquartered in Bothell, Washington. Its shares are listed on the NASDAQ under the ticker BLFS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- biolifesolutions.com
BioLife Solutions GekkoIndex: the smart money zone
BioLife Solutions’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.2, in the Neutral zone, up 5.8 points over five sessions.
52.2Neutral
Up 5.8 points over five sessions.
Reading for Oct 5, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 18 | +8.9% | +9.0% | ||
| Accumulation | 190 | +2.4% | +2.9% | ||
| Neutral (current zone) | 438 | 0.0% | +2.6% | ||
| Distribution | 31 | −2.6% | +2.0% | ||
| Selling | 1 | Too few readings yet | |||
Average BLFS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BLFS price, zone by zone.Track BLFS in Gekko
Is BioLife Solutions stock overvalued? Gekko Fair Value
BioLife Solutions trades 14.2% above Gekko Fair Value of $33.82, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what BioLife Solutions shares are worth, recalculated every trading day.
$33.82
Gekko Fair Value, Oct 9, 2026
14.2% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BLFS in Gekko
BioLife Solutions insider and Congress trading
No open-market insider purchases were filed for BioLife Solutions, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BLFS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BLFS, plotted on the chart in Gekko.Open BLFS in Gekko
Buybacks
BioLife Solutions has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $4.25M
- As a share of market cap
- 0.23%
From company filings.
BioLife Solutions earnings: next date and track record
BioLife Solutions reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.05
- Revenue estimate
- $29.13M
6 of 8reports beat the EPS estimate
±7.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 12, 2026 | $0.04 est $0.00 | — | −3.4% |
| Nov 6, 2025 | $0.04 est −$0.01 | $28.07M est $25.69M | −5.9% |
| Aug 7, 2025 | −$0.33 est −$0.03 | $25.42M est $25.69M | +7.5% |
| May 7, 2025 | $0.04 est −$0.04 | $23.94M est $22.22M | +1.9% |
| Feb 26, 2025 | −$0.02 est −$0.06 | — | −6.2% |
| Nov 12, 2024 | −$0.02 est −$0.09 | $30.57M est $21.55M | −9.4% |
| Aug 8, 2024 | −$0.50 est −$0.14 | $19.72M est $23.95M | +14.5% |
| May 9, 2024 | −$0.23 est −$0.28 | $18.43M est $26.01M | +8.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BioLife Solutions stock forecast and analyst price targets
Analysts’ average 12-month price target for BioLife Solutions is $31.00, −19.7% from the last close, from 8 firms rating the stock in the last 90 days.
$31.00consensus 12-month target, −19.7% from the last close
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 29 | Craig-Hallum | — | — |
| Sep 9 | Lake Street | $31 | −19.7% |
| Aug 10 | Benchmark Co. | — | — |
| Aug 7 | TD Cowen | $31 | −19.7% |
| Aug 7 | Lake Street | $31 | −19.7% |
+2.6%average 20-day move after past Neutral readings
+5.6%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BioLife Solutions seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, BioLife Solutions averaged +5.6% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 3 of 5 |
| Next 10 trading days | −3.6% | 2 of 5 |
| Next 15 trading days | +7.3% | 4 of 5 |
| Next 20 trading days | +5.6% | 2 of 5 |
| Next 30 trading days | +5.4% | 4 of 5 |
For scale, BLFS’s typical 20-trading-day move in either direction is about 9.9%.
BioLife Solutions market cap and key statistics
BioLife Solutions’s market cap is $1.89B, with a P/E ratio of 39 and revenue of $106.7M over the last twelve months.
Valuation
- Market cap
- $1.89B
- P/E ratio
- 39
- Forward P/E
- 238.1
- EPS, TTM
- $0.99
- Gekko Fair Value
- $33.82
Trading
- Volume
- 4.45M
- Avg volume, 20 days
- 1.20M
- 52-week high
- $39.76
- 52-week low
- $17.86
- Shares outstanding
- 48.92M
Financials
- Revenue, TTM
- $106.7M
- Profit margin
- 54.3%
- Return on equity
- 12.8%
- Quarterly earnings growth, YoY
- −13.9%
Risk and income
- Beta
- 1.82
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±9.9%
BioLife Solutions stock news this week
Coverage of BioLife Solutions this week reads neutral: 3 positive, 10 neutral and 5 negative headlines.
- Stock awards vested at about 200% of grants for BioLife Solutions (BLFS) CEO before merger dispositions.Stock Titan, Oct 9
- Form 4 BIOLIFE SOLUTIONS INC For: 8 October By Investing.comInvesting.com Nigeria, Oct 9
- Awards vest at about 200% as BioLife Solutions (BLFS) CFO disposes of shares in merger.Stock Titan, Oct 9
- After a merger disposition of 26,857 shares, BioLife Solutions (BLFS) director reports zero direct shares.Stock Titan, Oct 9
- A director disposes of 13,871 BioLife Solutions (BLFS) shares in a merger, leaving no direct shares.Stock Titan, Oct 9
- After disposing of 57,995 merger shares, BioLife Solutions (BLFS) director Ellingson holds none directly.Stock Titan, Oct 9
BioLife Solutions peers
BioLife Solutions’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
BioLife Solutions stock FAQ
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.89B at the Oct 5, 2026 close of $38.61, with 48.92M shares outstanding. The shares trade on a P/E ratio of 39.
What is the BioLife Solutions stock forecast?
The consensus analyst 12-month price target for BioLife Solutions is $31.00, −19.7% from the last close. Of the 8 firms that rated the stock in the last 90 days, 0 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BioLife Solutions stock overvalued or undervalued?
On Gekko’s estimate BioLife Solutions is overvalued: the Oct 5, 2026 close of $38.61 is 14.2% above Gekko Fair Value of $33.82. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BioLife Solutions report earnings next?
BioLife Solutions is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.05 per share on revenue of $29.13M. BioLife Solutions beat the earnings estimate in 6 of its last 8 reports, moving 7.2% on average across the report.
What is BioLife Solutions’s 52-week high and low?
BioLife Solutions’s 52-week high is $39.76 and its 52-week low is $17.86; it closed at $38.61 on Oct 5, 2026, +49.0% over the past year. Over the last five years the shares peaked at $58.80 on Nov 3, 2021.
Is BioLife Solutions stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 2 as mixed (gekkoindex and seasonality) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BioLife Solutions the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.